[Development of Stevens-Johnson syndrome following sulindac administration in a patient with mixed connective tissue disease].
Nineteen-year-old woman with mixed connective tissue disease developed Stevens-Johnson syndrome following treatment of arthritis using sulindac. Involvements of infectious and malignant diseases have been ruled out and sulindac has strongly been suspected as a causative agent for Stevens-Johnson syndrome. Ten out of 13 cases with Stevens-Johnson syndrome associated with non-steroidal anti-inflammatory drugs, sulindac has been administrated. Four cases also presented with severe liver disease. Patients who developed Stevens-Johnson syndrome following sulindac administration did not have apparent common clinical or laboratory findings which might be implicated for development of this severe side effects. Among the various non-steroidal anti-inflammatory drugs, safety of sulindac has widely been appreciated. However, occurrence of severe adverse events as reported here indicated that sulindac should be administrated as carefully as other non-steroidal anti-inflammatory drugs.
Awaya
N
N
Department of Medicine, Keio University School of Medicine, Tokyo.
Fujii
T
T
Akizuki
M
M
D000328:Adult; D056486:Chemical and Drug Induced Liver Injury; D002779:Cholestasis / Q000139:chemically induced; D005260:Female; D006801:Humans; D008947:Mixed Connective Tissue Disease / Q000188:drug therapy*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced*; D013467:Sulindac / Q000009:adverse effects*
D013467:Sulindac